Add to Favorites Newsroom RSS Share
Houston, TX USA

Our News on Newswise

MD Anderson and Berkeley Lights Launch Optera Therapeutics to Accelerate Development of Cell Therapies for Cancer

The University of Texas MD Anderson Cancer Center and Berkeley Lights, Inc. today announced the launch of Optera Therapeutics Corp, a biopharmaceutical company developing cell therapies with scalable manufacturing solutions for cancer.
6-Mar-2018 12:05 PM EST Add to Favorites


Deeper Look at Biopsy Exposes Mutation Ready to Ambush Drug Combination

A powerful resistance mutation that appeared to emerge in melanoma after a patient received a targeted therapy combination, instead was lurking in the tumor all along, primed to thwart treatment before it began, researchers at The University of...
2-Mar-2018 8:00 AM EST Add to Favorites

MD Anderson and RaySearch Announce Strategic Alliance to Advance Radiation Therapy of Cancer

The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing cancer radiation therapy through several initiatives, including more precisely targeting of tumors, and...
23-Feb-2018 12:05 PM EST Add to Favorites

MD Anderson Receives $22 Million in CPRIT Funding for Research, Prevention and Recruitment

The University of Texas MD Anderson Cancer Center was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30 percent of the $73.5 million in awards CPRIT announced today. The awards included $16.3...
21-Feb-2018 5:05 PM EST Add to Favorites


Kinase Inhibitor Larotrectinib Shows Durable Anti-Tumor Abilities in Patients of All Ages with 17 Unique Cancer Diagnoses

Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses.
20-Feb-2018 5:05 PM EST Add to Favorites


Obesity Associated with Longer Survival for Men with Metastatic Melanoma

Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), investigators report in a study published in Lancet Oncology of 1,918 patients in six...
12-Feb-2018 8:05 AM EST Add to Favorites


Smart Bomb Virus Shows Promise as Brain Tumor Immunotherapy

A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center...
12-Feb-2018 10:05 AM EST Add to Favorites


Newly Identified Potential Therapeutic Approach Kills Triple-Negative Breast Cancer Cells in Pre-Clinical Study

Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone cancer that accounts for one-fourth of all breast cancers, could be the focus of a new area of study for immune checkpoint blockade therapy. A team of researchers at The...
9-Feb-2018 12:00 PM EST Add to Favorites

see all news

Our Experts on Newswise


Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT


Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT


MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT


Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT


MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

see all experts

Our YouTube Videos

Chat now!